FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972600997> ?p ?o ?g. }

• W1972600997 endingPage "758" @default.
• W1972600997 startingPage "757" @default.
• W1972600997 abstract "Tay et al. proposed recently a new quadruple therapy after the failure of a first-line therapy for eradicating Helicobacter pylori.1 They reported an impressive eradication rate of >95%.1 However, they prescribed this regimen according to preantibiotic sensitivity testing based on bacterial culture. Although this approach seems to achieve a higher eradication rate, it may not be suitable for use in primary care. Current Maastricht IV guidelines still advise clarithromycin-based 7-day triple therapy in areas of low clarithromycin resistance,2 although clarithromycin resistance is very high worldwide, ranging from <10% in Northern Europe to 18.9% in Asia and 29.3% in America.3 However, this does not reflect the current eradication rate worldwide using this therapeutic regimen. In fact, its success rate has remained stable in the Far East as, for example, occurred from 2000 to 2010 in South Korea (86.7% vs. 88.3%, P = 0.06).4 On the contrary, in our experience, its effectiveness decreased significantly during the last decade or so. From January 1996 to December 2006, we treated 1497 dyspeptic patients with standard 7-day triple therapy (PPI-amoxycillin-clarithromycin). The overall H. pylori eradication rate was 70.4% (on intention-to-treat analysis). However, looking at the trend during the observation period, we found that it decreased significantly from 90.0% (95% CI: 87.1–93.9) in 1996 to 51.1% (95% CI: 48.1–55.9) in 2006 on intention-to-treat analysis (P = 0.001). It was well tolerated, with adverse events occurring in 7.9% (95% CI: 4.7–10.1) of the overall population, and only 1.4% of the overall population (95% CI: 0.33–3.6) had to discontinue treatment and withdraw from the study. After multivariate analysis, only smoking habit influenced eradication rates. Several other factors, ranging from adherence to therapy to age at the time of treatment, were assessed, but none were significant (see Table 1). Why this difference between Italy and other countries has occurred remains unclear, but it needs more in-depth analysis. In terms of using culture in managing resistant H. pylori infection, performing culture systematically in primary care has some limitations. Culture is not always available on a routine basis, it is expensive and time-consuming, especially when a low bacterial load is present,5 the sensitivity is not 100%, and therefore the antimicrobial susceptibility cannot be obtained in all cases6; and antibiotic susceptibility testing in clinical practice yields useful information only with respect to a few antibiotics. In our experience, levofloxacin-containing sequential therapy can be used as an alternative strategy.7 In conclusion, the optimal first-line H. pylori eradication therapy has yet to be discovered. Preantibiotic sensitivity testing should be used with caution, due to several limitations that affect the test yet. Declaration of personal and funding interests: None." @default.
• W1972600997 created "2016-06-24" @default.
• W1972600997 creator A5012022582 @default.
• W1972600997 date "2013-03-05" @default.
• W1972600997 modified "2023-10-17" @default.
• W1972600997 title "Letter: curingHelicobacter pyloriinfection in a clinical setting" @default.
• W1972600997 cites W1988694279 @default.
• W1972600997 cites W1997699780 @default.
• W1972600997 cites W2109391465 @default.
• W1972600997 cites W2111942462 @default.
• W1972600997 doi "https://doi.org/10.1111/apt.12226" @default.
• W1972600997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23458537" @default.
• W1972600997 hasPublicationYear "2013" @default.
• W1972600997 type Work @default.
• W1972600997 sameAs 1972600997 @default.
• W1972600997 citedByCount "1" @default.
• W1972600997 countsByYear W19726009972013 @default.
• W1972600997 crossrefType "journal-article" @default.
• W1972600997 hasAuthorship W1972600997A5012022582 @default.
• W1972600997 hasConcept C126322002 @default.
• W1972600997 hasConcept C197934379 @default.
• W1972600997 hasConcept C2776409635 @default.
• W1972600997 hasConcept C2776962512 @default.
• W1972600997 hasConcept C2781413609 @default.
• W1972600997 hasConcept C71924100 @default.
• W1972600997 hasConcept C90924648 @default.
• W1972600997 hasConceptScore W1972600997C126322002 @default.
• W1972600997 hasConceptScore W1972600997C197934379 @default.
• W1972600997 hasConceptScore W1972600997C2776409635 @default.
• W1972600997 hasConceptScore W1972600997C2776962512 @default.
• W1972600997 hasConceptScore W1972600997C2781413609 @default.
• W1972600997 hasConceptScore W1972600997C71924100 @default.
• W1972600997 hasConceptScore W1972600997C90924648 @default.
• W1972600997 hasIssue "7" @default.
• W1972600997 hasLocation W19726009971 @default.
• W1972600997 hasLocation W19726009972 @default.
• W1972600997 hasOpenAccess W1972600997 @default.
• W1972600997 hasPrimaryLocation W19726009971 @default.
• W1972600997 hasRelatedWork W1720840500 @default.
• W1972600997 hasRelatedWork W1996926164 @default.
• W1972600997 hasRelatedWork W2004456493 @default.
• W1972600997 hasRelatedWork W2017591175 @default.
• W1972600997 hasRelatedWork W2020359969 @default.
• W1972600997 hasRelatedWork W2073972370 @default.
• W1972600997 hasRelatedWork W2171452673 @default.
• W1972600997 hasRelatedWork W2391098947 @default.
• W1972600997 hasRelatedWork W2481853320 @default.
• W1972600997 hasRelatedWork W36606032 @default.
• W1972600997 hasVolume "37" @default.
• W1972600997 isParatext "false" @default.
• W1972600997 isRetracted "false" @default.
• W1972600997 magId "1972600997" @default.
• W1972600997 workType "letter" @default.